Doximity shares soar 21% after company beats on revenue, raises fiscal-year guidance

Doximity shares soar 21% after company beats on revenue, raises fiscal-year guidance


Doximity at the New York Stock Exchange for its initial public offering on June 24, 2021.

Source: NYSE

Shares of Doximity popped 21% on Thursday after the company reported third-quarter fiscal 2025 results that beat analysts’ expectations for revenue and offered rosy guidance.

Here’s how the company did:

  • Earnings per share: 37 cents, may not compare with the 34 cents expected by LSEG
  • Revenue: $168.6 million vs. $152.8 million expected by LSEG

Doximity is a digital platform for medical professionals that helps clinicians stay current on medical news, manage paperwork, find referrals and carry out telehealth appointments with patients. The company primarily generates revenue through its telehealth tools, hiring solutions and marketing offerings for clients such as pharmaceutical companies.

Doximity’s revenue increased 25% in its third quarter from $135.3 million during the same period last year, according to a release.

For its fiscal fourth quarter, Doximity said it expects to report revenue between $132.5 million and $133.5 million, compared with analysts’ estimates of $123.8 million.

The company also raised guidance for its full fiscal year, and said it expects to report revenue between $564.6 million and $565.6 million, up from the range the company shared last quarter, when it expected $535 million to $540 million. Analysts were expecting $540 million for the year.

“We’re proud to deliver another quarter of record engagement in Q3, with over 610,000 unique providers using our clinical workflow tools,” Doximity CEO Jeff Tangney said in a statement. “Our AI tools grew the fastest last quarter, up 60% over the prior quarter, while our newsfeed surpassed more than one million unique providers.”

The company reported net income of $75.2 million, or 37 cents per share, during its third quarter, up from $48.0 million, or 24 cents per share, a year prior. Doximity’s adjusted EBITDA was $102.0 million, up 39% year over year.

Doximity has been a bright spot within the battered digital health sector, which has faced a reckoning as companies have had to adjust to a more muted growth environment. The company’s stock price more than doubled in 2024.

Don’t miss these insights from CNBC PRO



Source

Software stocks plunge on ServiceNow, IBM results as AI fears escalate
World

Software stocks plunge on ServiceNow, IBM results as AI fears escalate

Signage outside the ServiceNow headquarters in Santa Clara, California, US, on Thursday, Sept. 4, 2025. David Paul Morris | Bloomberg | Getty Images Software stocks plummeted on Thursday as disappointing results from ServiceNow and IBM added to fears that artificial intelligence tools and services will disrupt their businesses. Shares of ServiceNow sank 17% Thursday, on […]

Read More
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
World

Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment

Roche reported falling sales in the first three months of the year, as the strength of the Swiss franc and generic competition for some of its older drugs weighed on the drugmaker.  First-quarter sales came in at 14.7 billion Swiss francs ($18.7 billion), down 5% year-on-year — but up 6% on a constant currency basis. […]

Read More
These charts show how Iran’s economy is in freefall
World

These charts show how Iran’s economy is in freefall

An Iranian salesperson sits beside a portrait of Iran’s late Supreme Leader Ayatollah Ali Khamenei at his fruit shop in the Shahid Boroujerdi residential complex in southern Tehran, Iran, on April 14, 2026. Morteza Nikoubazl | Nurphoto | Getty Images The war in the Middle East is plunging Iran’s already fragile economy into freefall. Tehran’s […]

Read More